D J Heal

Summary

Affiliation: RenaSci Consultancy Ltd
Country: UK

Publications

  1. ncbi request reprint The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety
    D J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham NG1 1GF, UK
    Neuropharmacology 57:608-18. 2009
  2. doi request reprint ADHD: Current and Future Therapeutics
    David J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, NG1 1GF, UK
    Curr Top Behav Neurosci 9:361-90. 2012
  3. ncbi request reprint A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil
    David J Heal
    RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK
    Neuropharmacology 73:348-58. 2013
  4. pmc Amphetamine, past and present--a pharmacological and clinical perspective
    David J Heal
    RenaSci Limited, BioCity, Nottingham, UK
    J Psychopharmacol 27:479-96. 2013
  5. doi request reprint A review of late-stage CNS drug candidates for the treatment of obesity
    D J Heal
    RenaSci Consultancy Limited, BioCity, Nottingham, UK
    Int J Obes (Lond) 37:107-17. 2013
  6. ncbi request reprint What is the prognosis for new centrally-acting anti-obesity drugs?
    David J Heal
    RenaSci Consultancy Limited, BioCity, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Neuropharmacology 63:132-46. 2012
  7. ncbi request reprint Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders
    D J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, NG1 1GF, UK
    Pharmacol Ther 117:207-31. 2008
  8. doi request reprint New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD
    D J Heal
    RenaSci Consultancy Limited, BioCity, Nottingham NG1 1GF, UK
    Pharmacol Biochem Behav 90:184-97. 2008
  9. pmc Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
    David J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, UK
    Br J Clin Pharmacol 68:861-74. 2009
  10. ncbi request reprint Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system
    David J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, UK
    CNS Drugs 20:713-38. 2006

Collaborators

Detail Information

Publications30

  1. ncbi request reprint The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety
    D J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham NG1 1GF, UK
    Neuropharmacology 57:608-18. 2009
    ..This review will discuss the in vivo pharmacological profiles of approved catecholaminergic drugs for treatment of ADHD and implications for their clinical efficacy and abuse liability...
  2. doi request reprint ADHD: Current and Future Therapeutics
    David J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, NG1 1GF, UK
    Curr Top Behav Neurosci 9:361-90. 2012
    ..The treatment of ADHD is also described from the perspective of the physician. Finally, the new research development for drugs to treat ADHD is discussed...
  3. ncbi request reprint A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil
    David J Heal
    RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK
    Neuropharmacology 73:348-58. 2013
    ..Lisdexamfetamine did not serve as a positive reinforcer in cocaine-trained rats, and although it generalised fully to D-amfetamine, its discriminative effects were markedly influenced by its unusual pharmacokinetics...
  4. pmc Amphetamine, past and present--a pharmacological and clinical perspective
    David J Heal
    RenaSci Limited, BioCity, Nottingham, UK
    J Psychopharmacol 27:479-96. 2013
    ..How lisdexamfetamine's distinctive pharmacokinetic/pharmacodynamic profile translates into sustained efficacy as a treatment for ADHD and its reduced potential for recreational abuse is also discussed...
  5. doi request reprint A review of late-stage CNS drug candidates for the treatment of obesity
    D J Heal
    RenaSci Consultancy Limited, BioCity, Nottingham, UK
    Int J Obes (Lond) 37:107-17. 2013
    ..In this review we briefly describe the therapeutic approaches to tackle obesity that are in late-stage clinical development. We then discuss drugs in late-stage development for the treatment of obesity and also future directions...
  6. ncbi request reprint What is the prognosis for new centrally-acting anti-obesity drugs?
    David J Heal
    RenaSci Consultancy Limited, BioCity, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Neuropharmacology 63:132-46. 2012
    ..This article is part of a Special Issue entitled 'Central Control of Food Intake'...
  7. ncbi request reprint Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders
    D J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, NG1 1GF, UK
    Pharmacol Ther 117:207-31. 2008
    ....
  8. doi request reprint New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD
    D J Heal
    RenaSci Consultancy Limited, BioCity, Nottingham NG1 1GF, UK
    Pharmacol Biochem Behav 90:184-97. 2008
    ..When the findings are compared with the clinical efficacy of drugs used in treating ADHD, they indicate that the most efficacious drugs powerfully increase both norepinephrinergic and dopaminergic neurotransmission...
  9. pmc Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
    David J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, UK
    Br J Clin Pharmacol 68:861-74. 2009
    ..The regulatory environment for antiobesity drugs and the spectrum of indications for which they can be approved could change dramatically if positive data for sibutramine emerge from the SCOUT outcome trial...
  10. ncbi request reprint Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system
    David J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, UK
    CNS Drugs 20:713-38. 2006
    ....
  11. ncbi request reprint Quantification of presynaptic alpha 2-adrenoceptors in rat brain after short-term DSP-4 lesioning
    D J Heal
    Boots Pharmaceuticals Research Department, Nottingham, UK
    Eur J Pharmacol 249:37-41. 1993
    ....
  12. ncbi request reprint Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats
    H L Rowley
    BASF Pharma Research and Development, Nottingham, UK
    Synapse 38:167-76. 2000
    ..These findings therefore suggest that dopaminergic reward mechanisms are not involved in the reduction of food intake by sibutramine. Furthermore, they are consistent with the view that sibutramine lacks abuse potential...
  13. ncbi request reprint Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats
    H L Rowley
    CNS Biology, Knoll Pharmaceuticals Research and Development, Nottingham, UK
    Neuropharmacology 37:937-44. 1998
    ..These data suggest that the inhibition of NA uptake by zotepine and its subsequent prolonged elevation of extracellular cortical NA may underlie the reported antidepressant properties of zotepine in schizophrenic patients...
  14. ncbi request reprint Receptor binding and functional evidence suggest that postsynaptic alpha 2-adrenoceptors in rat brain are of the alpha 2D subtype
    D J Heal
    Boots Pharmaceuticals Research Department, Nottingham, UK
    Eur J Pharmacol 277:215-21. 1995
    ..224; P = 0.670) or alpha 2C-adrenoceptors (r = 0.253; P = 0.584). These data are, therefore, consistent and argue strongly that postsynaptic alpha 2-adrenoceptors in the rat cortex and Edinger-Westphal nucleus are of the alpha 2D subtype...
  15. ncbi request reprint Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activit
    H L Rowley
    RenaSci Consultancy Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK
    Neuropharmacology 63:1064-74. 2012
    ..These findings help explain why the unusual pharmacokinetics of lisdexamfetamine evoked lower "Drug liking" scores than IR d-amfetamine and also suggest therapeutic window between efficacy and stimulant side-effects will be larger...
  16. ncbi request reprint Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine
    S C Cheetham
    BASF Pharma, Research and Development, Nottingham NG1 1GF, UK
    Neuropharmacology 39:2028-35. 2000
    ..These data provide further evidence that sibutramine is a 5-HT re-uptake inhibitor and it does not have neurotoxic potential...
  17. ncbi request reprint A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo
    H L Rowley
    Biology, BASF Pharma Research and Development, Nottingham, UK
    Naunyn Schmiedebergs Arch Pharmacol 361:187-92. 2000
    ..Furthermore, the ability of zotepine to elevate cortical DA is more likely to derive from its inhibition of the NA transporter rather than DA receptor blockade in this region...
  18. ncbi request reprint An investigation of the role of 5-hydroxytryptamine in the attenuation of presynaptic alpha 2-adrenoceptor-mediated responses by antidepressant treatments
    D J Heal
    Research Department, Boots Company PLC, Nottingham, UK
    Psychopharmacology (Berl) 101:100-6. 1990
    ..The probable explanation for a contrasting requirement for a functional 5-HT input is that desipramine and ECS induce this common adaptive response by different pharmacological mechanisms...
  19. ncbi request reprint Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile
    P L Needham
    Knoll Pharmaceuticals Research Department, Nottingham, UK
    Psychopharmacol Bull 32:123-8. 1996
    ..Since a stimulation imbalance favoring D1 over D2 receptors has been suggested to induce dyskinesias, zotepine's reduced EPS profile in humans may derive, in part, from balanced inhibition of these receptors...
  20. ncbi request reprint KTX 0101: a potential metabolic approach to cytoprotection in major surgery and neurological disorders
    Sharon L Smith
    RenaSci Consultancy Ltd, BioCity, Nottingham, NG1 1GF, UK
    CNS Drug Rev 11:113-40. 2005
    ..These issues are being addressed by designing and synthesizing orally bioavailable multimers of betaOHB with improved pharmacokinetics...
  21. ncbi request reprint Obesity drug development - CBI's 2nd Annual Summit
    David J Heal
    RenaSci Consultancy Ltd, BioCity, Nottingham, NG1 1GF, UK
    IDrugs 9:682-5. 2006
  22. ncbi request reprint Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release
    I C Kilpatrick
    Knoll Limited Research and Development, Nottingham, UK
    Int J Obes Relat Metab Disord 25:1454-8. 2001
    ..The ability of phentermine to inhibit both MAO(A) and MAO(B) in vitro has been examined along with that of the fenfluramine isomers, a range of selective serotonin reuptake inhibitors and sibutramine and its active metabolites...
  23. ncbi request reprint Determination of body composition in conscious adult female Wistar utilising total body electrical conductivity
    K Dickinson
    Knoll Ltd, Research and Development, R3 Pennyfoot Street, NG1 1GF, Nottingham, UK
    Physiol Behav 74:425-33. 2001
    ..003) indicating stability of the calibration equation with time and independence from operator. We therefore conclude that it is possible to meaningfully estimate body fat changes in conscious rats using this TOBEC analysis system...
  24. ncbi request reprint Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine
    M R Prow
    Knoll Limited, Research and Development, Nottingham, UK
    Int J Obes Relat Metab Disord 25:1450-3. 2001
    ..CONCLUSIONS: This study provides evidence that phentermine's actions are not restricted to catecholamine systems and indicates that combining phentermine with dexfenfluramine results in an additive increase in neuronal 5HT release...
  25. ncbi request reprint Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors
    Yong Ling Liu
    Department of Physiology, St George s Hospital Medical School, University of London, Tooting, London SW17 0RE, UK
    Eur J Pharmacol 452:49-56. 2002
    ..Duloxetine shares these properties, but is generally less efficacious. Any potential weight-reducing effect of bupropion is probably due to thermogenesis...
  26. pmc Differences in the mechanisms that increase noradrenaline efflux after administration of d-amphetamine: a dual-probe microdialysis study in rat frontal cortex and hypothalamus
    Sandrine M Géranton
    Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, U K
    Br J Pharmacol 139:1441-8. 2003
    ....
  27. ncbi request reprint Noradrenaline clearance differs in the frontal cortex and hypothalamus: a dual-probe microdialysis study in freely-moving rats
    Sandrine M Géranton
    Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK
    Neurosci Lett 350:157-60. 2003
    ....
  28. ncbi request reprint Acute cardiovascular effects of sibutramine in conscious rats
    Jeanette Woolard
    School of Biomedical Sciences, University of Nottingham Medical School, Queen s Medical Centre, Nottingham, UK
    J Pharmacol Exp Ther 308:1102-10. 2004
    ..It remains to explain why BTS 54354, but not BTS 54505, enhanced norepinephrine sensitivity in vitro, because both metabolites are potent inhibitors of the norepinephrine transporter...
  29. ncbi request reprint Pharmacological characterisation of the thermogenic effect of bupropion
    Yong Ling Liu
    Department of Physiology, Basic Medical Sciences, St George s Hospital Medical School, Tooting, London, SW17 0RE, UK
    Eur J Pharmacol 498:219-25. 2004
    ..Because bupropion has also been reported not to alter food intake in the clinic, thermogenesis may also contribute to its antiobesity effect in man...
  30. ncbi request reprint 5-HT has contrasting effects in the frontal cortex, but not the hypothalamus, on changes in noradrenaline efflux induced by the monoamine releasing-agent, d-amphetamine, and the reuptake inhibitor, BTS 54 354
    Sandrine M Géranton
    Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK
    Neuropharmacology 46:511-8. 2004
    ..These findings suggest that serotonergic transmission has complex effects on the noradrenergic response to drugs that increase noradrenergic transmission in the frontal cortex, but has less influence in the hypothalamus...